Advance Cell Therapy Development

CDX models offer controlled tumor expression systems ideal for proof-of-concept and potency studies during early therapy development.

Organoids provide human-relevant, scalable in vitro systems for co-culture and functional assays, bridging the gap between discovery and in vivo validation.

Our biomarker suite includes key targets like BCMA, CD19, CD20, and CD22 immune phenotyping, cytokine and transcriptome profiling, and multiplex imaging to correlate activity with therapeutic response.

With unmatched translational model diversity and scientific expertise, Crown Bioscience provides integrated solutions to accelerate and de-risk cell therapy development.

Crown Bioscience provides a comprehensive portfolio of translational models—including patient-derived organoids and PDX models—that accurately reflect clinical expression of key cell therapy targets such as BCMA, CD19, CD20, and CD22. These models enable high-confidence target validation, functional testing, and safety assessment for CAR-T and other engineered cell therapies. With well-annotated molecular profiles and reproducible performance, our models help streamline preclinical decision-making and improve the predictability of cell therapy development.